Get the Stockscreener App
25.21
1.33%
-0.34
After Hours:
25.20
-0.01
-0.04%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $25.21, with a volume of 48.78M.
It is down -1.33% in the last 24 hours and down -4.58% over the past month.
See More
Previous Close:
$25.55
Open:
$25.52
24h Volume:
48.78M
Relative Volume:
1.21
Market Cap:
$148.25B
Revenue:
$63.63B
Net Income/Loss:
$8.03B
P/E Ratio:
17.88
EPS:
1.41
Net Cash Flow:
$9.84B
1W Performance:
-3.82%
1M Performance:
-4.58%
6M Performance:
-12.98%
1Y Performance:
-8.63%
1-Day Range:
$25.12
$25.65
1-Week Range:
$25.12
$26.52
52-Week Range:
$24.48
$31.54
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.21 | 148.25B | 63.63B | 8.03B | 9.84B | 1.41 |
|
LLY
Lilly Eli Co
|
826.76 | 742.57B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
201.30 | 356.10B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
161.72 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
71.73 | 334.39B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
88.11 | 235.20B | 64.17B | 17.12B | 18.10B | 6.73 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Feds probe tip that Pfizer delayed announcing COVID vaccine’s success until after 2020 election: report - New York Post
Exclusive | U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine - The Wall Street Journal
Market Today: Pfizer Faces Investigation, Microsoft Scales Back Data Centers - GuruFocus.com
Here's Why Pfizer (PFE) Fell More Than Broader Market - Yahoo Finance
US prosecutors probe tip about timing of Pfizer's COVID vaccine, WSJ reports - Reuters
Pfizer Shares Are Down Today: What's Going On? - Benzinga
Pfizer shares dip amid U.S. vaccine probe reports By Investing.com - Investing.com Australia
Pfizer shares dip amid U.S. vaccine probe reports - Investing.com
Pfizer stock drops after U.S. probe on COVID shot (PFE:NYSE) - Seeking Alpha
Pfizer falls after report says US probing tip about timing of COVID vaccine - TradingView
US Prosecutors Investigate Tip on Pfizer Vaccine - Marketscreener.com
US Prosecutors Investigate Tip on Pfizer Vaccine, Wall Street Journal Reports - Marketscreener.com
US Prosecutors Probe Tip About Timing Of Pfizer VaccineWSJ - Marketscreener.com
Moderna, Novavax, and Pfizer shares fall amid U.S. vaccine fund cuts By Investing.com - Investing.com South Africa
Moderna, Novavax, and Pfizer shares fall amid U.S. vaccine fund cuts - Investing.com
Pfizer’s CX Vision: Powered by People, Fueled by Data - CMSWire
ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program - Quantisnow
Pfizer Stock Slips After Report on Vaccine Timing Probe - The Wall Street Journal
Drug Co. Wants Fed. Circ. To Undo Pfizer COVID Patent Win - Law360
Pfizer: Undervalued Defensive Play - Yahoo Finance
Pfizer Is Trading As If It's 2009 Again (NYSE:PFE) - Seeking Alpha
Which is the Healthiest Investment: Merck or PfizerF.A.S.T. GraphsCommentaries - Advisor Perspectives
Broadcom and Crown Castle in the Box have been highlighted as Zacks Bull and Bear of the Day - TradingView
USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars? - Crowell & Moring LLP
Is Pfizer (PFE) The Best Affordable Stock To Buy According To Hedge Funds? - Insider Monkey
Pfizer Is A Dirt-Cheap High-Yield Stock, But Is It A Buy? - Barchart
China touted its business potential at a meeting with Apple, Pfizer and other US companies - Українські Національні Новини
Pfizer Is a Dirt-Cheap High-Yield Stock, But Is It a Buy? - Zacks Investment Research
Pfizer Inc. (PFE) Stock: Is This Healthcare Giant the Bargain of 2025? - MoneyCheck
Epinephrine Market Is Booming Worldwide 2025-2032 | Pfizer, - openPR
China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing 'Will Continue To Improve The Business Environment' - MSN
China reassures Apple, Pfizer, Cargill, others of business potential - TradingView
China's vice premier reassures Apple, Pfizer, Cargill, others of business potential - TradingView
Is Pfizer Inc. (PFE) The Best Healthcare Dividend Stock to Invest in? - Insider Monkey
Former Pfizer chief scientist joins Immunai’s board of directors - The Jerusalem Post
With 67% ownership, Pfizer Inc. (NYSE:PFE) boasts of strong institutional backing - Yahoo Finance
Pfizer: Bulls Need To Check Out Its Graham P/E - Seeking Alpha
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move - The Motley Fool
Looking For Yields: Pfizer, Spire, And TriCo Bancshares Are Consistent Moneymakers - Benzinga
Pfizer Wraps Up Haleon Exit With $3.3 Billion Stake Sale - MSN
Chemistry Students Explore Cutting-Edge Technology at Pfizer Laboratories - CSUF News
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - Yahoo Finance
Pfizer Completes Sale of Entire Stake in Haleon PLC - TipRanks
Alnylam Heart Drug Approval Sets Up Challenge With Pfizer - Yahoo Finance
Haleon Completes GBP170 Million Share Buyback Deal With Pfizer -March 21, 2025 at 09:16 am EDT - Marketscreener.com
Alnylam shares rise on expanded heart drug approval -March 21, 2025 at 07:32 am EDT - Marketscreener.com
Haleon PLC Completes Share Repurchase from Pfizer - TipRanks
Rx Rundown: AstraZeneca, Pfizer, Novartis and more - MM+M Online
Pfizer to Exit Sensodyne-Maker Haleon With Final Stake Sale - MSN
Dyslexia Treatment Market Is Booming Worldwide 2025-2032 | - openPR
Chemotherapy Market Overall Study Report 2025-2032 | AstraZeneca, Pfizer Inc., Novartis AG, GSK plc., Sanofi - openPR
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.71%
1.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):